Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
نویسندگان
چکیده
منابع مشابه
Successful treatment of a spontaneous haemothorax with recombinant factor VIIa in a haemophilic child with inhibitors.
Haemophilia A is an X-linked disorder caused by a deficiency of factor VIII. Haemorrhage in various sites may occur spontaneously or secondary to trauma depending on the severity of the deficiency. Common manifestations include haemarthrosis, epistaxis, gastrointestinal haemorrhage and haematuria. Spontaneous haemothorax has rarely been reported both in children and adults1,2. We report the cas...
متن کاملEffect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Recombinant factor VIIa (rF.VIIa) is a two-chain procoagulant enzyme (Mr, approximately 50,000) active only when complexed with tissue factor in the extrinsic clotting system. We administered human rF.VIIa to hemophilic and von Willebrand disease (vWD) dogs to determine its hemostatic effectiveness and survival in the circulation. Hemophilia A dogs lacking factor VIII demonstrated an immediate ...
متن کاملCost Minimization Analysis of Activated Prothrombin Complex Concentrate (Apcc) Compared To Recombinant Factor Viia (Rfviia) for Hemophilia Patients With Inhibitors.
REFERENCES [1] Bonnet, P., et al. „Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.“ Haemophilia (2009): 1-7. [2] Astermark, J., et al. „A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Compar...
متن کاملInhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
Recombinant factor VIIa (rFVIIa) is a novel prohemostatic drug for patients with hemophilia who have developed inhibitory antibodies. The postulation has been made that hemophilia is not only a disorder of coagulation, but that hyperfibrinolysis due to a defective activation of thrombin activatable fibrinolysis inhibitor (TAFI) might also play a role. In this in vitro study, the potential of rF...
متن کاملThe evidence behind inhibitor treatment with recombinant factor VIIa.
Over the past 10 years considerable use has been made of recombinant factor VIIa (rFVIIa) for the treatment of patients with inhibitors to coagulation factors. During this time, its place in the management of acute bleeds and surgery has become better defined. Although pharmacokinetic studies report the half-life of rFVIIa as 2.7 h, there is considerable intersubject variability. Moreover, rFVI...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: TH Open
سال: 2017
ISSN: 2512-9465
DOI: 10.1055/s-0037-1608943